<DOC>
	<DOC>NCT02382796</DOC>
	<brief_summary>The purpose of this study to permit continued access to dacomitinib for patients who participated in other dacomitinib monotherapy treatment protocols in Japan and have the potential to derive clinical benefit without unacceptable toxicity from continued dacomitinib treatment.</brief_summary>
	<brief_title>A Rollover Protocol of Dacomitinib For Patients In Japan</brief_title>
	<detailed_description>The intention of the study is to allow continued use of dacomitinib in Japan for patients on closed dacomitinib clinical trials and who continue to experience clinical benefit.</detailed_description>
	<criteria>Patients who received dacomitinib on another clinical trial in Japan Evidence of a personally signed and dated informed consent document Patients who meet one or more study withdrawal criteria on the prior study Participation in other studies involving other investigational drug(s) during study participation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>